Physician Assistant · Columbus, OH
NPI
1730726621
Since 2019
Specialty
Physician Assistant
Code 363A00000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
500 Thomas Ln Ste 3a
Columbus, OH, 43214
Phone (614) 566-2500
Groups this clinician bills Medicare through
Medicare paid, 2024
$5,648
75 services
Medicare patients, 2024
42
Average age 77
Drug cost, 2024
$4.1M
654 prescriptions
Company payments, 2025
$605
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Cassady Remy was code 99214 (office e&m - established), 29 times for 19 patients. In total Cassady Remy billed 75 services in 5 codes, and Medicare paid $5,648.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 29 | 19 | $72.71 | $2,109 |
| 38222 Other Organ Systems | Facility | 21 | 20 | $59.83 | $1,256 |
By year: 2022 $2,030 for 34 services; 2023 $2,872 for 53 services; 2024 $5,648 for 75 services.
Medicare prescription drug claims, 2024
In 2024, the drug Cassady Remy prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 65 prescriptions and refills. In total Cassady Remy wrote 654 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 65 | 71 | 11 | $1.1M |
| Valacyclovir Valacyclovir Hcl | 62 | 89 | 18 | $1,940 |
| Hydroxyurea Generic | 49 | 74 | 14 | $712 |
| Venclexta Venetoclax | 44 | 44 | 15 | $124K |
| Imatinib Mesylate Generic | 38 | 38 | Under 11 | $57K |
| Levofloxacin Generic | 32 | 32 | 18 | $510 |
| Sprycel Dasatinib | 31 | 31 | Under 11 | $288K |
| Iclusig Ponatinib Hcl | 29 | 29 | Under 11 | $590K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 27 | 39 | 12 | $107 |
| Posaconazole Generic | 25 | 25 | Under 11 | $19K |
| Scemblix Asciminib Hydrochloride | 19 | 19 | Under 11 | $395K |
| Pegasys Peginterferon Alfa-2a | 16 | 20 | Under 11 | $68K |
| Fluconazole Generic | 14 | 15 | Under 11 | $701 |
| Prednisone Generic | 11 | 11 | Under 11 | $62.25 |
| Tibsovo Ivosidenib | 11 | 11 | Under 11 | $344K |
Brand drugs: 287 claims; generic drugs: 367 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Cassady Remy $605 ($605 in general payments such as food, travel and fees) from 11 companies. The largest payer was Novartis Pharmaceuticals Corporation with $167.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 7 | $167 |
| Sobi, Inc SOBI.ST | 3 | $79.34 |
| Azurity Pharmaceuticals, Inc. | 2 | $60.82 |
| Astellas Pharma US Inc 4503.T | 2 | $55.96 |
| Daiichi Sankyo Inc. 4568.T | 2 | $55.35 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $47.6 |
| GlaxoSmithKline, LLC. GSK | 1 | $33.36 |
| Janssen Biotech, Inc. JNJ | 1 | $33.05 |
| Adaptive Biotechnologies Corporation ADPT | 1 | $27.83 |
| Pfizer Inc. PFE | 1 | $24.48 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.